Project Grant R56DE028905
- Federal Grant Award Summary Old Dominion University Research Foundation received a $583,826 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), effective August 14, 2025, through August 13, 2028. The grant funds research to develop pre-vascularization strategies for an integrated three-dimensional human osteo-mucosal model, building upon the awardee's previously completed NIH-funded work...
- Federal Grant Award Summary Virginia Commonwealth University received a $101,828 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded December 1, 2026, with completion targeted for May 9, 2028. The award supports basic research focused on the functional and structural characterization of phospholipase A2 (PLA2) enzyme, specifically the PG1879 protein, in Porphyromonas gingivalis, a...
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded the University of Toledo a Project Grant of $947,264 under the Oral Diseases and Disorders Research program (CFDA 93.121), effective May 1, 2025, through April 30, 2028. This three-year research initiative investigates IL-17 (Interleukin-17) receptor signaling in megakaryocytes and its role in oral mucosal immune responses during oropharyngeal candidiasis (OPC) caused by Candida albicans. The...
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded The Johns Hopkins University a $521,362 Project Grant on August 12, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate neuroimmune interactions in craniofacial bone healing. The research project, which extends through August 11, 2027, seeks to decode the signaling mechanisms between nerves, immune cells, and bone-forming cells during cranial bone repair....
- Federal Grant Award Summary Oregon Health & Science University received a $121,667 Project Grant from the National Institute of Dental and Craniofacial Research under the Oral Diseases and Disorders Research program (CFDA 93.121), effective April 1, 2026, through March 31, 2028. This award funds the synthesis, characterization, and validation of novel granular hydrogel platforms for the theranostic (simultaneous therapeutic and diagnostic) management of periodontitis, an oral inflammatory...
- Federal Grant Award Summary New York University received a Project Grant of $1,345,320 from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) for the project "Fibronectin Modulation of Oral Cancer Nociception." The award, effective August 21, 2025 through August 20, 2027, supports research aimed at identifying non-opioid therapeutic targets for managing oral cancer pain. The project addresses a...
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $249,000 Project Grant to Boston University Medical Campus, effective May 1, 2026 through April 30, 2031, under the Oral Diseases and Disorders Research program (CFDA 93.121). This five-year research initiative will investigate the mechanisms underlying pulpitis—a painful inflammatory disease of the dental pulp—by examining the complex interactions between neutrophils and sensory neurons. The...
- Federal Grant Award Summary Virginia Commonwealth University received a $427,208 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), effective August 12, 2025, with a completion date of May 31, 2030. The award funds research into a novel immunotherapeutic agent called hFlagRP170, designed to enhance head and neck squamous cell carcinoma (HNSCC) responsiveness to standard cancer...
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded the University of Illinois a Project Grant of $217,100.00 under the Oral Diseases and Disorders Research program (CFDA 93.121) effective March 1, 2030. This award supports a structured training and research initiative designed to develop the applicant as a clinician-scientist in craniofacial and oral sciences. The program delivers mentoring, career development support, and professional...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded The Ohio State University a Project Grant totaling $690,195 under the Oral Diseases and Disorders Research program (CFDA 93.121) on March 1, 2026, with completion scheduled for February 28, 2031. This research initiative investigates the neuroimmunological mechanisms regulating reparative dentinogenesis—the process of dentin repair following deep tooth injuries and inflammation. The...
Old Dominion University Research Foundation (ODURF) received a $933,580 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) for the period June 1, 2026 through May 31, 2028. The award funds research into an immunomodulatory approach to improve oral cavity wound healing, specifically targeting oronasal fistula (ONF) formation complications that occur in approximately 60% of cleft palate surgeries and following traumatic oral injury or dental procedures. The research will investigate FTY720, an active biolipid compound that targets the sphingosine pathway to preferentially attract pro-regenerative immune cells and reduce inflammatory responses during oral wound healing. The funded research will deliver mechanistic insights into the immunoregenerative function of FTY720 during oral cavity wound healing and optimize its delivery as the first oral regenerative therapy. Key research objectives include determining the mechanisms by which FTY720 reduces inflammatory neutrophils, monocytes, and macrophages through genetic, epigenetic, and sphingolipid pathways, and optimizing the chemical structure of FTY720 to enhance its therapeutic efficacy. The expected outcomes will address a significant clinical need by providing regenerative treatment options to reduce pain, improve surgical outcomes, and eliminate the need for multiple revision surgeries currently required for ONF complications.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $933.6k | 5/26/26 |